

Evogliptin tartrate

Chemical Properties


CAS No. : 1222102-51-3

Formula: C₂₃H₃₂F₃N₃O₉

Molecular Weight: 551.51

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation. Evogliptin tartrate is a potent, orally bioavailable and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, with antidiabetic activity.
Targets(IC50)	Proteasome,DPP-4,Autophagy
In vitro	Evogliptin tartrate inhibits the TNF- α -mediated transcriptional activation of ICAM-1 and VCAM-1. Evogliptin tartrate inhibits inflammatory responses via suppression of adhesion molecules induced by TNF- α . And TNF- α -mediated activation of NF- κ B is ameliorated by evogliptin via the interaction of NF- κ B with SIRT1.Evogliptin tartrate significantly inhibits the TNF- α -mediated induction of ICAM-1 and VCAM-1 expression in a concentration-dependent manner (IC ₅₀ = 0.30 and 0.25 μ M, respectively).
In vivo	Evogliptin tartrate inhibits the formation of atherosclerotic lesions by reducing vasoinflammation and increases plaque stability.Evogliptin tartrate (37.5-150 mg/kg; p. o.; daily; for 12 weeks) reduces the high-fat diet-induced atherosclerotic plaque area in the ApoE ^{-/-} mouse model.

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8132 mL	9.066 mL	18.132 mL
5 mM	0.3626 mL	1.8132 mL	3.6264 mL
10 mM	0.1813 mL	0.9066 mL	1.8132 mL
50 mM	0.0363 mL	0.1813 mL	0.3626 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Modulation of Sirt1/NF- κ B interaction of evogliptin is attributed to inhibition of vascular inflammatory response leading to attenuation of atherosclerotic plaque formation. *Biochem Pharmacol.* 2019 Oct;168:452-464.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481